StreetInsider.com News Articles

Form 10-Q CV Sciences, Inc. For: Mar 31

Fri, 15 May 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260515/26505494.html

Form 10-Q CV Sciences, Inc. For: Mar 31

Fri, 15 May 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260515/26505494.html

CV Sciences (CVSI) Reports Q1 EPS of $0.00

Thu, 14 May 2026 16:06:59 -0400

CV Sciences (OTC: CVSI) reported Q1 EPS of $0.00. Revenue for the quarter came in at $3.2 million.

For earnings history and earnings-related data on CV Sciences (CVSI) click here.

Form 8-K CV Sciences, Inc. For: May 14

Thu, 14 May 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260514/26494600.html

Form 8-K CV Sciences, Inc. For: May 14

Thu, 14 May 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260514/26494600.html

CV Sciences, Inc. Reports First Quarter-End 2026 Financial Results

Thu, 14 May 2026 16:00:00 -0400

SAN DIEGO, CA / ACCESS Newswire / May 14, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended March 31, 2026.

First Quarter 2026 and Recent Financial and Operating Highlights

Generated revenue of $3.2 million for the first quarter 2026 compared to $3.6 million for the first quarter 2025 and compared to $3.3 million for the fourth quarter 2025;
Recognized gross margin of

CV Sciences, Inc. Reports First Quarter-End 2026 Financial Results

Thu, 14 May 2026 16:00:00 -0400

First Quarter 2026 and Recent Financial and Operating Highlights

Generated revenue of $3.2 million for the first quarter 2026 compared to $3.6 million for the first quarter 2025 and compared to $3.3 million for the fourth quarter 2025;
Recognized gross margin of

CV Sciences, Inc. To Announce First Quarter 2026 Results On May 14, 2026

Tue, 12 May 2026 18:00:00 -0400

SAN DIEGO, CA / ACCESS Newswire / May 12, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, today announced that it will release financial results for the first quarter ended March 31, 2026, after the stock market closes on Thursday, May 14, 2026. The Company will hold a conference call with the investment community at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) that same day.

The webcast

CV Sciences, Inc. To Announce First Quarter 2026 Results On May 14, 2026

Tue, 12 May 2026 18:00:00 -0400

The webcast

Form DEF 14A CV Sciences, Inc. For: Apr 15

Wed, 15 Apr 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260415/26314219.html

Form DEF 14A CV Sciences, Inc. For: Apr 15

Wed, 15 Apr 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260415/26314219.html

Form 8-K CV Sciences, Inc. For: Apr 06

Fri, 10 Apr 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260410/26299875.html

Form 8-K CV Sciences, Inc. For: Apr 06

Fri, 10 Apr 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260410/26299875.html

Form 10-K CV Sciences, Inc. For: Dec 31

Thu, 26 Mar 2026 17:14:00 -0400

si-local-file:///var/storage/secattach/20260326/26225701.html

Form 10-K CV Sciences, Inc. For: Dec 31

Thu, 26 Mar 2026 17:14:00 -0400

si-local-file:///var/storage/secattach/20260326/26225701.html

Form 8-K CV Sciences, Inc. For: Mar 26

Thu, 26 Mar 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260326/26224391.html

Form 8-K CV Sciences, Inc. For: Mar 26

Thu, 26 Mar 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260326/26224391.html

CV Sciences, Inc. Reports Fiscal Year-End 2025 Financial Results

Thu, 26 Mar 2026 16:00:00 -0400

SAN DIEGO, CA / ACCESS Newswire / March 26, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the year and quarter ended December 31, 2025.

Fiscal 2025, Fourth Quarter 2025 and Recent Financial and Operating Highlights

Generated revenue of $13.8 million for fiscal 2025 compared to $15.7 million for 2024; Revenue of $3.3 million for the fourth quarter 2025 compared to $3.9 million for

CV Sciences, Inc. Reports Fiscal Year-End 2025 Financial Results

Thu, 26 Mar 2026 16:00:00 -0400

Fiscal 2025, Fourth Quarter 2025 and Recent Financial and Operating Highlights

Generated revenue of $13.8 million for fiscal 2025 compared to $15.7 million for 2024; Revenue of $3.3 million for the fourth quarter 2025 compared to $3.9 million for

CV Sciences, Inc. To Announce Year End and Fourth Quarter 2025 Results On March 26, 2026

Tue, 24 Mar 2026 17:00:00 -0400

SAN DIEGO, CA / ACCESS Newswire / March 24, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, today announced that it will release financial results for the year end and fourth quarter ended December 31, 2025, after the stock market closes on Thursday, March 26, 2026. The Company will hold a conference call with the investment community at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) that

CV Sciences, Inc. To Announce Year End and Fourth Quarter 2025 Results On March 26, 2026

Tue, 24 Mar 2026 17:00:00 -0400

Form 8-K CV Sciences, Inc. For: Oct 07

Tue, 10 Mar 2026 17:17:00 -0400

si-local-file:///var/storage/secattach/20260310/26140667.html

Form 8-K CV Sciences, Inc. For: Oct 07

Tue, 10 Mar 2026 17:17:00 -0400

si-local-file:///var/storage/secattach/20260310/26140667.html

CV Sciences Announces Successful Debt Restructuring Designed to Strengthen Financial Position and Fuel Future Growth

Tue, 10 Mar 2026 17:00:00 -0400

SAN DIEGO, CA / ACCESS Newswire / March 10, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in proven, science-backed natural ingredients and products, today announced that it has modified its existing outstanding notes to include a conversion feature pursuant to which the outstanding balance of the notes may be converted into common shares of the Company at a fixed conversion price of $0.06 per share.

"We are pleased with the successful completion of a comprehensive debt restructuring, marking a significant

CV Sciences Announces Successful Debt Restructuring Designed to Strengthen Financial Position and Fuel Future Growth

Tue, 10 Mar 2026 17:00:00 -0400

"We are pleased with the successful completion of a comprehensive debt restructuring, marking a significant